Baillie Gifford & Co. Lowers Position in Quanterix Co. (NASDAQ:QTRX)

Baillie Gifford & Co. decreased its stake in shares of Quanterix Co. (NASDAQ:QTRX) by 1.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 623,355 shares of the company’s stock after selling 8,218 shares during the period. Baillie Gifford & Co. owned about 1.63% of Quanterix worth $14,686,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. AJOVista LLC purchased a new position in Quanterix during the 4th quarter worth $81,000. Picton Mahoney Asset Management purchased a new position in shares of Quanterix in the 4th quarter worth approximately $139,000. Quest Partners LLC purchased a new stake in shares of Quanterix during the fourth quarter valued at approximately $240,000. Los Angeles Capital Management LLC purchased a new position in Quanterix in the fourth quarter worth $285,000. Finally, Graham Capital Management L.P. bought a new position in Quanterix in the 3rd quarter valued at $287,000. Institutional investors own 86.48% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group decreased their price objective on shares of Quanterix from $32.00 to $25.00 and set a “buy” rating for the company in a report on Monday, April 29th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Quanterix presently has an average rating of “Buy” and an average target price of $30.60.

Quanterix Price Performance

NASDAQ:QTRX traded down $0.29 on Friday, reaching $12.23. 208,009 shares of the company’s stock were exchanged, compared to its average volume of 529,370. The stock has a fifty day simple moving average of $15.47 and a 200-day simple moving average of $20.87. Quanterix Co. has a 52 week low of $11.83 and a 52 week high of $29.70. The firm has a market cap of $468.04 million, a price-to-earnings ratio of -12.74 and a beta of 1.39.

Quanterix (NASDAQ:QTRX) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.07. Quanterix had a negative net margin of 28.82% and a negative return on equity of 10.39%. The company had revenue of $32.07 million during the quarter, compared to the consensus estimate of $31.72 million. As a group, sell-side analysts predict that Quanterix Co. will post -0.86 EPS for the current year.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.